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Myoﬁbroblastoma (MFB) is a rare mesenchymal tumor arising in breast’s soft tissue with a great variety of microscopic features
that can be mistaken with a wide variety of biphasic lesions. The authors report a rare case of myoﬁbroblastoma of the breast
arising in a mammary hamartoma (MH), present a review of the clinicopathological features of these lesions, and make some
diagnostic considerations. The tumour consisted of a well-circumscribed nodule. MFB component comprised about ﬁfty percent
of the lesion and was made up of bipolar spindle cells arranged in fascicular clusters separated by bands of hyalinized collagen.
There were fat cells and several residual hamartoma glands intermingled and distorted in MFB area. MFB component was positive
for Desmin, CD34, bcl-2, and Calponin. To the best of our knowledge, MFB has not been reported in MH, neither has any of the
reports described mammary glands joined within MFB.
1.Introduction
Myoﬁbroblastoma (MFB) is a rare mesenchymal tumor
arising in breast’s soft tissue [1, 2]. In 1987, Wargotz et al.
[2] described a benign tumour of the breast composed of
spindle cells arranged in fascicular clusters with interspersed
bands of hyalinized collagen and called this lesion “myoﬁ-
broblastoma”. After that, several cases have subsequently
been reported, and it has become clear that MFB of the
breastmayexhibitagreatervarietyofmorphologicalfeatures
thanoriginallydescribed.Glandularstructureshavenotbeen
described in MFB [3–9].
Mammary hamartomas (MH) comprise about 0.7% of
all benign breast masses that were ﬁrst described in 1928
by Prym [10], who referred to them as “mastomas”. Further
caseswerereportedasadenolipomasandﬁbroadenolipomas.
In 1971, Arrigoni was the ﬁrst to introduce the term
mammary hamartoma, that is further characterized by the
variety of mature tissues they contain [11].
The authors report a case of MFB developed in MH. This
very rare association may be a potential diagnostic pitfall in
the spectrum of biphasic cell lesions of the breast. To our
knowledge, the coexistence of MFB and MH in the same
mass has not been published.
2.CaseReport
A 59-year-old woman presented with a solitary nodule in the
left breast which was ﬁrst noted on routine mammography.
Left breast echography showed a sharply demarcated nodule
inthebreastparenchyma.Acompletesurgicalexcisionofthe
mass was performed.
Gross pathology showed a well-circumscribed, round
to slightly lobulated, tan, rubbery, 2,5cm nodule. On cut
sections, a whitish tumour mass with scanty interspersed
yellow areas was evident. Microscopically, the tumour had
pushing borders and was circumscribed by a pseudocapsule.
At scanning magniﬁcation, we noticed two distinct tumoral2 Pathology Research International
Figure 1: Mammary myoﬁbroblastoma: the lesion shows bundles
of slender, uniform, spindle shaped cells typically arranged in
clustersandbandsofhyalinizedcollagendistributedthroughoutthe
tumor, HE, 100x.
Figure 2: Mammary hamartoma: the process is composed of
mammary glandular tissue with a lobular arrangement, ﬁbrous
stroma, and adipose tissue in variable proportions, HE, 100x.
regions. In the “hypercellular area”, classic features of
myoﬁbroblastoma of breast were present (Figure 1). The
“hypocellular area” revealed a lesion containing scattered
epithelial elements embedded in collagenized stroma, typical
of mammary hamartoma (Figure 2). The MFB area was
composed of bundles of spindle cells with eosinophilic
cytoplasm and elongated monomorphic nuclei, adopting a
fascicular arrangement and separated by thick collagenous
stromal bands (Figure 3). In the stroma, there were scant
mature adipocytes, large numbers of mast cells, occasional
lymphoid aggregates, and several residual benign-appearing
glands. The epithelial elements “entrapped” in the MFB
area were not diﬀerent from the other ones scattered in
the MH area. The MFB-MH transitional area was subtle.
No mitotic ﬁgures, atypical cells, areas of necrosis, smooth
muscle, or cartilaginous diﬀerentiation were observed. The
immunohistochemical proﬁle of MFB component revealed
the strong and diﬀuse staining for Vimentin, Desmin, and
CD34 (Figure 4) and focal positivity for Calponin (Figure 5)
and bcl-2. Alpha-smooth muscle actin, Actin, S-100 protein,
and CD99 and CD10 were negative. The stroma of MH
showed diﬀuse staining for vimentin, and the epithelial ele-
ments revealed strong CK7 positivity and focal positivity for
bcl-2. Cytokeratin 7 highlighted several residual hamartoma
Figure 3: Mammary myoﬁbroblastoma: tumor composed of a
homogeneous population of spindle-shaped cells with ovoid nuclei
and pale cytoplasm, HE, 400x.
Figure 4: Positive immunoreactivity for CD34 in mammary
myoﬁbroblastoma, avidin-biotin technique, 100x.
glands admixed to the MFB area. In addition, myoepithelial
cells of hamartoma glands were easily identiﬁed. There was
variable immunoreactivity for Alpha-smooth muscle actin,
Calponin, Actin, S-100 protein, and CD10. No recurrence
or other complaints have been experienced after a 1-year
followup period.
3. Discussion
Primary mesenchymal neoplasms of the breast parenchyma
like myoﬁbroblastoma are extremely uncommon, represent-
ing less than 1% of mammary neoplasms [1–3]. MFB occurs
in the breast of women between 40 and 80 years, referring
to a solitary slowly growing nodule. Macroscopically, it is a
well-circumscribed encapsulated tumor raging in size from
1,0cm to 10cm. Histologically, MFB is an expansile tumor
with pushing borders, composed of spindle to oval cells
arranged in short, intersecting fascicles, and interrupted by
thick bands of collagen. The cells have relatively abundant,
ill-deﬁned, eosinophilic cytoplasm with a round to oval
nucleus. Necrosis is usually absent. There is a low mitotic
index, and it is uncommon entrapment of mammary ducts
or lobules within the tumor. Scattered mast cells may
be seen in the stroma. The neoplastic cells are usuallyPathology Research International 3
Figure 5: Positive immunoreactivity for calponin in mammary
myoﬁbroblastoma, avidin-biotin technique, 100x.
immunopositive for vimentin, desmin, CD34, and alpha-
smooth muscle actin. There is variable immunostaining
for bcl-2 protein, CD99, and estrogen and progesterone
receptors. Some cases can show lipomatous, smooth muscle,
or cartilaginous components [3, 6–9].
MFB may exhibit a great variety of morphological
features, including inﬁltrating margins and epithelioid com-
ponent, that can be similar to other spindle-cell benign
tumours of the breast, like solitary ﬁbrous tumour (SFT)
and spindle cell lipoma (SCL) [2, 3, 7–9]. Mammary MFB
and SCL usually have abundant stromal mast cells, and the
spindle cells are CD34-positive, but the former is typically
positive for desmin. MFB consistently expresses positive
muscle immunomarkers in contrary with SFT. Additional
evidence of a histologic continuum between MFB, SCL, and
SFT has been provided by other reports employing bcl-2,
CD10 and CD99 antibodies [3, 6–9]. The MFB spindle-cell
area of our tumour expressed bcl2, but not CD10 and CD99
like others reported [3, 6–9].
MH is further characterized by the presence of a dense
hyalinized ﬁbrotic stroma, interlobular ﬁbrosis, variable
volume of mature adipose tissue, and pseudoangiomatous
hyperplasia [1, 3, 5, 11, 12]. In our paper, the MH area
of the breast lump showed all of these features. There are
several reports describing primary ductal or lobular breast
cancer arising in MH, but neither of these had yet published
a fusiform neoplasia arising within MH [1–3, 5, 13, 14].
Because glandular structures interspersed within MFB
are a very rare unpublished ﬁnding, some biphasic lesions of
the breast, such as adenomyoepithelioma (AME), phyllodes
tumor (PT), or even cellular ﬁbroadenoma (CFA), have
never been regarded in the diﬀerential diagnosis of MFB.
So, this unique tumor association (MFB in MH) may be a
potential diagnostic pitfall in the spectrum of biphasic cell
lesions of the breast [3, 14–19]. The fusiform components
of both lesions (CFA and PT) do not show bundles of
spindle cells in a fascicular arrangement separated by thick
collagen ﬁbers, neither do they have the typical strong and
diﬀuse staining for Desmin and CD34 expressed by MFB
spindle cells. Adenomyoepitheliomas usually do not exhibit
the thicker bands of hyalinized collagen and are negative for
CD34. Entrapped fat cells virtually do not occur in AME too,
but mast cells have been found [3, 7, 13, 16, 17, 19].
The diﬀerential diagnosis of MFB of the breast can
include other reactive processes and benign neoplasms such
as nodular fasciitis, ﬁbromatosis, neuroﬁbroma, leiomyoma,
stromal sarcoma, malignant ﬁbrous histiocytoma, metaplas-
ticcarcinoma,spindlecellliposarcoma,low-grademalignant
peripheral nerve sheath tumor, and dermatoﬁbrosarcoma
protuberans [2–4, 7, 9, 16, 17].
4. Conclusion
Herein, we report a rare case of MFB developed in MH.
To the best of our knowledge, this peculiar morphological
ﬁnding has not been previously reported yet. This very
rare association may be a potential diagnostic pitfall in
the spectrum of biphasic cell lesions of the breast. The
immunohistochemical study of the lesion will be useful.
Nevertheless, the simple histologic examination of the entire
lesion straightforward turned our diagnosis. In the present
nodule, there was a large typical MH area comprising about
ﬁfty percent of the mass. Therefore, it was somewhat logical
topresumethattheentrappedepithelialelementsintheMFB
component werevestiges of theMH. Itcouldbe verydiﬃcult
to be sure about MFB with entrapped hamartoma epithelial
elements without the entire analysis of our tumor.
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